Fig. 3From: Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysisForest plot of the long-term prognostic outcomes of anti-PD-1/PD-L1 monotherapy (non-smoker vs. smoker), PNon-smoker = 0.304, PSmoker < 0.001Back to article page